{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:03:59Z","timestamp":1784819039634,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Wuxi medical and health guidance plan for scientific and technological development","award":["NZ2019004"],"award-info":[{"award-number":["NZ2019004"]}]},{"name":"Jiangsu Pharmaceutical Association-Aosaikang Hospital Pharmacy Fund","award":["A201729"],"award-info":[{"award-number":["A201729"]}]},{"name":"Jiangsu Pharmaceutical Association-Tianqing Hospital Pharmacy Fund","award":["Q2019087"],"award-info":[{"award-number":["Q2019087"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.intimp.2020.106749","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T08:28:22Z","timestamp":1593592102000},"page":"106749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"special_numbering":"C","title":["Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19"],"prefix":"10.1016","volume":"86","author":[{"given":"Xiuhong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhen","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.106749_b0005","doi-asserted-by":"crossref","unstructured":"Y. Zhao, Z.X. Zhao, Y.J. Wang, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov, BioRxiv (2020) https:\/\/doi.org\/10.1101\/2020.01.26.919985 (access 3 Jun 2020).","DOI":"10.1101\/2020.01.26.919985"},{"key":"10.1016\/j.intimp.2020.106749_b0010","doi-asserted-by":"crossref","unstructured":"W.J. Guan, Z.Y. Ni, Y. Hu, et al., Clinical characteristics of 2019 novel coronavirus infection in China, MedRxiv (2020) https:\/\/doi.org\/10.1101\/2020.02.06.20020974 (access 20 Feb 2020).","DOI":"10.1101\/2020.02.06.20020974"},{"key":"10.1016\/j.intimp.2020.106749_b0015","unstructured":"K.J. Xu, H.L. Cai, Y.H. Shen, et al., Management of corona virus disease-19 (COVID-19): the Zhejiang experience, Zhejiang Da Xue Xue Bao (Yi Xue Ban) (2020) http:\/\/kns.cnki.net\/kcms\/detail\/33.1248.R.20200222.1417.002.html (in Chinese) (access 3 Mar 2020)."},{"key":"10.1016\/j.intimp.2020.106749_b0020","unstructured":"J.W. Zhang, X. Hu, P.F. Jin, Cytokine storm induced by SARS-CoV-2 and the drug therapy. Zhongguo Yao Xue Za Zhi (2020) http:\/\/kns.cnki.net\/kcms\/detail\/11.2162.R.20200225.1052.002.html (in Chinese) (access 9 Feb 2020)."},{"key":"10.1016\/j.intimp.2020.106749_b0025","doi-asserted-by":"crossref","unstructured":"S.Y. Zhang, L. Li, A.Z. Shen, et al., Rational use of tocilizumab in the treatment of novel coronavirus pneumonia, Clin. Drug Investig. (2020) https:\/\/doi.org\/10.1007\/s40261-020-00917-3 (access 29 Apr 2020).","DOI":"10.1007\/s40261-020-00917-3"},{"issue":"2","key":"10.1016\/j.intimp.2020.106749_b0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2020.106749_b0035","first-page":"380","article-title":"Analysis of pathogens and risk factors for death in elderly patients with severe pneumonia","volume":"29","author":"Fei","year":"2019","journal-title":"Zhong Hua Yi Yuan Gan Ran Xue Za Zhi"},{"issue":"7","key":"10.1016\/j.intimp.2020.106749_b0040","first-page":"1007","article-title":"Correlation between inflammatory factor expression level in severe pneumococcal alveolar lavage fluid and prognosis","volume":"29","author":"Ma","year":"2019","journal-title":"Zhong Hua Yi Yuan Gan Ran Xue Za Zhi"},{"issue":"10223","key":"10.1016\/j.intimp.2020.106749_b0045","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2020.106749_b0050","unstructured":"L. Chen, H.G. Liu, W. Liu, et al., Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhong Hua Jie He He Hu Xi Za Zhi (2020) https:\/\/doi.org\/10.3760\/cma.j.issn.1001-0939.2020.0005 (in Chinese) (access 15 Feb 2020)."},{"key":"10.1016\/j.intimp.2020.106749_b0055","doi-asserted-by":"crossref","unstructured":"S.X. Wan, Q.J. Yi, S.B. Fan, et al., Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv (2020) https:\/\/doi.org\/10.1101\/2020.02.10.20021832 (access 20 Feb 2020).","DOI":"10.1101\/2020.02.10.20021832"},{"key":"10.1016\/j.intimp.2020.106749_b0060","doi-asserted-by":"crossref","unstructured":"J. Liu, S.M. Li, J. Liu, et al., Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. MedRxiv (2020) https:\/\/doi.org\/10.1101\/2020.02.16.20023671 (access 3 Mar 2020).","DOI":"10.1016\/j.ebiom.2020.102763"},{"key":"10.1016\/j.intimp.2020.106749_b0065","doi-asserted-by":"crossref","unstructured":"P. Conti, G. Ronconi, A. Caraffa, et al., Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J. Biol. Regul. Homeost. Agents (2020) https:\/\/doi.org\/10.23812\/CONTI-E (access 29 Apr 2020).","DOI":"10.23812\/CONTI-E"},{"issue":"10223","key":"10.1016\/j.intimp.2020.106749_b0070","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2020.106749_b0075","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12964-018-0268-4","article-title":"Activation of the JAK\/STAT3 and PI3K\/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells","volume":"16","author":"Zegeye","year":"2018","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.intimp.2020.106749_b0080","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"12","key":"10.1016\/j.intimp.2020.106749_b0085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106749_b0090","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2020.106749_b0095","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","article-title":"Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs","volume":"104","author":"Gadina","year":"2018","journal-title":"J. Leukoc. Biol."},{"issue":"10224","key":"10.1016\/j.intimp.2020.106749_b0100","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2020.106749_b0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.str.2015.12.015","article-title":"Family-wide structural analysis of human numb-associated protein kinases","volume":"24","author":"Sorrell","year":"2016","journal-title":"Structure"},{"issue":"5","key":"10.1016\/j.intimp.2020.106749_b0110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.vph.2005.09.002","article-title":"Introduction to JAK\/STAT signaling and the vasculature","volume":"43","author":"Marrero","year":"2005","journal-title":"Vasc. Pharmacol."},{"issue":"8","key":"10.1016\/j.intimp.2020.106749_b0115","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1089\/jir.2014.0012","article-title":"Involvement of the janus kinase\/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis","volume":"34","author":"Benveniste","year":"2014","journal-title":"J. Interferon. Cytok. Res."},{"key":"10.1016\/j.intimp.2020.106749_b0120","doi-asserted-by":"crossref","unstructured":"P.J. Richardson, M. Corbellino, J. Stebbing, Baricitinib for COVID-19: a suitable treatment? - Authors' reply, Lancet Infect. Dis. (2020) https:\/\/doi.org\/10.1016\/S1473-3099(20)30270-X (access 29 Apr 2020).","DOI":"10.1016\/S1473-3099(20)30270-X"},{"issue":"9371","key":"10.1016\/j.intimp.2020.106749_b0125","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak or coronavirus-associated SARS pneumonia: a prospective study","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet"},{"issue":"10229","key":"10.1016\/j.intimp.2020.106749_b0130","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2020.106749_b0135","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.intimp.2020.106749_b0140","unstructured":"US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/home. (access 29 Apr 2020)."},{"key":"10.1016\/j.intimp.2020.106749_b0145","doi-asserted-by":"crossref","unstructured":"F. Cantini, L. Niccoli, D. Matarrese, et al., Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact, J. Infect. (2020) https:\/\/doi.org\/10.1016\/j.jinf.2020.04.017 (access 3 Jun 2020).","DOI":"10.1016\/j.jinf.2020.04.017"},{"key":"10.1016\/j.intimp.2020.106749_b0150","unstructured":"The U.S. Food and Drug Administration. Information for Olumiant (baricitinib) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924Orig1s000lbl.Pdf (access 25 Apr 2020)."},{"issue":"10143","key":"10.1016\/j.intimp.2020.106749_b0155","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2020.106749_b0160","doi-asserted-by":"crossref","unstructured":"E.L. Simpson, J.P. Lacour, L. Spelman, et al., Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials, Br. J. Dermatol. (2020) https:\/\/doi.org\/10.1111\/BJD.18898 (access 2 Jun 2020).","DOI":"10.1111\/bjd.18898"},{"key":"10.1016\/j.intimp.2020.106749_b0165","doi-asserted-by":"crossref","unstructured":"D. Praveen, R.C. Puvvada, M. Vijey Aanandhi, Baricitinib-a januase kinase inhibitor-not an ideal option for management of COVID-19, Int. J. Antimicrob. Ag. (2020) https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105967 (access 3 Jun 2020).","DOI":"10.1016\/j.ijantimicag.2020.105967"},{"issue":"1","key":"10.1016\/j.intimp.2020.106749_b0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2020.106749_b0175","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s10067-018-4199-7","article-title":"Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials","volume":"37","author":"Kunwar","year":"2018","journal-title":"Clin. Rheumatol."},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2020.106749_b0180","first-page":"308.2-309","article-title":"THU0078 safety profile of baricitinib for the treatment of rheumatoid arthritis up to 7 years: an updated integrated safety analysis","volume":"78","author":"Genovese","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2020.106749_b0185","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920314181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920314181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:53:19Z","timestamp":1769028799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920314181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":37,"alternative-id":["S1567576920314181"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106749","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106749"}}